Abstracts tagged "scleroderma and systemic sclerosis"

Abstract Number: 2910 • 2016 ACR/ARHP Annual Meeting
Work Productivity in Systemic Sclerosis and Association with Health Related Quality of Life
Kathleen Morrisroe¹, Molla Huq², Wendy Stevens³, Joanne Sahhar⁴, Susanna Proudman^5,6, Mandana Nikpour⁷ and Australian Scleroderma Interest Group, ¹Rheumatology, St Vincent's Hospital, Melbourne, Melbourne, Australia, ²Department of Medicine (Rheumatology), Melbourne University, Melbourne, Australia, ³Department of Rheumatology, St. Vincent’s Hospital Melbourne, Melbourne, Australia, ⁴Department of Rheumatology, Monash Medical Centre, Melbourne, Australia, ⁵Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, ⁶Discipline of Medicine, University of Adelaide, Adelaide, Australia, ⁷Melbourne University, Melbourne, Australia
Background/Purpose: We sought to assess work productivity, factors associated with reduced productivity, and the relationship between work productivity and health-related quality of life (HRQoL) in…
Abstract Number: 826 • 2016 ACR/ARHP Annual Meeting
Exercise Echocardiography Predicts Future Development of Pulmonary Hypertension in a High-Risk Cohort of Scleroderma Patients
Kaitlin A. Quinn¹, Tunay Kuru², Stephanie Wappel³ and Virginia D. Steen¹, ¹Rheumatology, Georgetown University Medical Center, Washington, DC, ²Pulmonary, Georgetown University Medical Center, Washington, DC, ³Georgetown University Medical Center, Washington, DC
Background/Purpose: Pulmonary hypertension (PH) is the leading cause of scleroderma related deaths and is often detected late in the disease course. Early identification of patients…
Abstract Number: 828 • 2016 ACR/ARHP Annual Meeting
Survival and Health-Related Quality of Life in Incident Systemic Sclerosis Related Pulmonary Arterial Hypertension: A Multicentre Australian Cohort Study
Kathleen Morrisroe¹, Molla Huq², Wendy Stevens³, Candice Rabusa⁴, Joanne Sahhar⁵, Gene Ngian⁶, Susanna Proudman^7,8, Mandana Nikpour⁹ and Australian Scleroderma Interest Group, ¹Rheumatology, St Vincent's Hospital, Melbourne, Melbourne, Australia, ²Department of Medicine (Rheumatology), Melbourne University, Melbourne, Australia, ³Department of Rheumatology, St. Vincent’s Hospital Melbourne, Melbourne, Australia, ⁴Rheumatology, St. Vincent’s Hospital, Melbourne, Australia, ⁵Department of Rheumatology, Monash Medical Centre, Melbourne, Australia, ⁶Department of Medicine (RMH/WH), The University of Melbourne, Melbourne, Australia, ⁷Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, ⁸Discipline of Medicine, University of Adelaide, Adelaide, Australia, ⁹Melbourne University, Melbourne, Australia
Background/Purpose: Pulmonary arterial hypertension (PAH) is the leading cause of systemic sclerosis (SSc) related mortality. We sought to determine survival, predictors of mortality, and health…
Abstract Number: 833 • 2016 ACR/ARHP Annual Meeting
A Small Proportion of Patients with Systemic Sclerosis with Suspected Pulmonary Hypertension Meet the Published Inclusion/Exclusion Criteria for Two Systemic Sclerosis Associated Pulmonary Arterial Hypertension Screening Algorithms– Results from a Single Center Cohort
Amber Young¹, Victor Moles², Vivek Nagaraja³, Scott H. Visovatti⁴, Vallerie McLaughlin⁴ and Dinesh Khanna⁵, ¹Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Department of Internal Medicine, Division of Cardiology, University of Michigan, Ann Arbor, MI, ³Department of Medicine [Division of Rheumatology], University of Toledo, Toledo, OH, ⁴Internal Medicine, Division of Cardiology, University of Michigan, Ann Arbor, MI, ⁵University of Michigan, Ann Arbor, MI
Background/Purpose: Pulmonary arterial hypertension (PAH) is one of the leading causes of mortality in patients with systemic sclerosis (SSc). Active screening detects SSc-PAH earlier and…
Abstract Number: 836 • 2016 ACR/ARHP Annual Meeting
Comprehensive Characterization of Calcinosis in a Multicenter International Cohort of Patients with Systemic Sclerosis
Antonia Valenzuela^1,2, Jessica K. Gordon³, Tatiana Sofia Rodriguez-Reyna⁴, Susanna Proudman^5,6, Murray Baron⁷, Monique Hinchcliff⁸, Dinesh Khanna⁹, Amber Young¹⁰, Flavia V. Castelino¹¹, Sara R. Schoenfeld¹², Virginia D. Steen¹³, David Fiorentino¹⁴ and Lorinda Chung¹⁵, ¹Division of Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ²Stanford University School of Medicine, Stanford, CA, ³Rheumatology, Hospital for Special Surgery, New York, NY, ⁴Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁵Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, ⁶Discipline of Medicine, University of Adelaide, Adelaide, Australia, ⁷Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada, ⁸Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, ⁹University of Michigan, Ann Arbor, MI, ¹⁰Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, ¹¹Rheumatology, Allergy, Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ¹²Rheumatology Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ¹³Rheumatology, Georgetown University Medical Center, Washington, DC, ¹⁴Department of Dermatology, Stanford University School of Medicine, Palo Alto, CA, ¹⁵Rheumatology, Stanford University Medical Center, Palo Alto, CA
Background/Purpose: Calcinosis cutis is a debilitating complication of systemic sclerosis (SSc) affecting one quarter of patients. Repetitive trauma may be involved in the pathogenesis of…
Abstract Number: 971 • 2016 ACR/ARHP Annual Meeting
Reliability and Minimal Clinically Important Differences (MCID) of Forced Vital Capacity: Post-Hoc Analyses from the Scleroderma Lung Studies (SLS-I and II)
Suzanne Kafaja¹, Philip J. Clements², Holly Wilhalme³, Daniel E. Furst⁴, Chi-hong Tseng², Kim Hyun⁵, Jonathan Goldin³, Elizabeth R. Volkmann³, Michael Roth², Donald P. Tashkin⁶ and Dinesh Khanna⁷, ¹Medicine/Rheumatology, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ³University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁵Radiology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, ⁶David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, ⁷University of Michigan, Ann Arbor, MI
Background/Purpose: Forced vital capacity (FVC) is used as a primary outcome measure in clinical trials of systemic sclerosis-related interstitial lung disease (SSc-ILD). Minimally Clinically Important…
Abstract Number: 973 • 2016 ACR/ARHP Annual Meeting
Clinical Characterization of Patients with World Health Organization Group 2 Pulmonary Hypertension in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Cohort
Jessica K. Gordon¹, Jackie Szymonifka², Matthew R. Lammi³, Virginia D. Steen⁴ and PHAROS Investigators, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Epidemiology and Biostatistics, Hospital for Special Surgery, New York, NY, ³Louisiana State University Health Sciences Center, Pulmonary and Critical Medicine, New Orleans, LA, ⁴Rheumatology, Georgetown University Medical Center, Washington, DC
Background/Purpose: Pulmonary hypertension (PH) is a leading cause of death in patients (pts) with Systemic Sclerosis (SSc). The World Health Organization (WHO) classifies PH into…
Abstract Number: 974 • 2016 ACR/ARHP Annual Meeting
Diffuse Scleroderma, Male Sex, and Myopathy Are Associated with Severe Gastrointestinal Dysmotility in Scleroderma
Zsuzsanna McMahan¹, Livia Casciola-Rosen² and Fredrick M. Wigley³, ¹Department of Internal Medicine, Johns Hopkins University, Baltimore, MD, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Rheum Div/Mason F Lord, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Despite the fact that up to 90% of scleroderma (SSc) patients are affected by gastrointestinal (GI) dysmotility, features associated with severe GI disease are…
Abstract Number: 1189 • 2016 ACR/ARHP Annual Meeting
Inpatient Trends for Adults with Scleroderma in the United States: A 20 Year Analysis
Noopur Goel¹, Ishan Lalani² and Iram Moledina³, ¹Internal Medicine, Monmouth Medical Center, monmouth beach, NJ, ²Internal Medicine, Monmouth Medical Center, Ocean, NJ, ³Gujarat Adani Institute of Medical Sciences, New Haven, CT
Abstract Number: 1432 • 2016 ACR/ARHP Annual Meeting
The EULAR Systemic Sclerosis Impact of Disease Score – a New Patient-Reported Outcome Measure for Patients with Systemic Sclerosis Under Development
Rucsandra Dobrota¹, Mike Becker², Kim Fligelstone^3,4, Jaap Fransen⁵, Ann Kennedy⁶, Yannick Allanore⁷, Patricia Carreira⁸, László Czirják⁹, Christopher Denton¹⁰, Roger Hesselstrand¹¹, Gunnel Sandqvist¹¹, Otylia Kowal-Bielecka¹², Marco Matucci Cerinic¹³, Carina Mihai¹⁴, Ana Maria Gheorghiu¹⁵, Ulf Müller-Ladner¹⁶, Marc Frerix¹⁷, Turid Heiberg¹⁸ and Oliver Distler¹, ¹Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ³Royal Free Hospital, Scleroderma Unit and Scleroderma Society, London, United Kingdom, ⁴Federation of European Scleroderma Associations (FESCA), London, United Kingdom, ⁵Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ⁶Federation of European Scleroderma Associations (FESCA), Tournai, Belgium, ⁷Department of Rheumatology, University Paris Descartes and Cochin Hospital, Paris, France, ⁸Department of Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ⁹Department of Rheumatology and Immunology, University of Pécs, Faculty of Medicine, Pécs, Hungary, ¹⁰Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ¹¹Department of Rheumatology, Lund University, Lund, Sweden, ¹²Department of Rheumatology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland, ¹³Department of Rheumatology, University of Florence, Florence, Italy, ¹⁴Department of Internal Medicine and Rheumatology, Carol Davila University of Medicine and Pharmacy, Cantacuzino Hospital, Bucharest, Romania, ¹⁵Carol Davila University of Medicine and Pharmacy, Internal Medicine and Rheumatology Department, Cantacuzino Clinical Hospital, Bucharest, Romania, ¹⁶Department of Internal Medicine and Rheumatology, Justus-Liebig-University Giessen, Kerckhoff-Klinik, Bad Nauheim, Germany, ¹⁷Department of Rheumatology and Clinical Immunology, Justus-Liebig-University Giessen, Kerckhoff-Klinik, Bad Nauheim, Germany, ¹⁸Department of Health and Social Sciences, Oestfold University College, Oslo, Norway
Background/Purpose: Patient reported outcome measures (PROM) are required as key outcomes in disease modifying therapeutic trials in systemic sclerosis (SSc). A PROM tool in SSc,…
Abstract Number: 1865 • 2016 ACR/ARHP Annual Meeting
Urinary Cell Adhesion Molecules As Markers of Renal Involvement in Systemic Sclerosis
Edward Stern¹, Voon H. Ong², Aine Burns³, Robert Unwin⁴ and Christopher Denton⁵, ¹UCL Division of Medicine, London, United Kingdom, ²Rheumatology, UCL Division of Medicine, London, United Kingdom, ³Nephrology, Royal Free Hospital, London, United Kingdom, ⁴Nephrology, UCL Division of Medicine, London, United Kingdom, ⁵Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom
Background/Purpose: Renal involvement in systemic sclerosis (SSc) includes scleroderma renal crisis as well as progressive organ fibrosis. Detection and management of these disease complications is…
Abstract Number: 1877 • 2016 ACR/ARHP Annual Meeting
Confirmatory Factor Analysis and Assessment of Differential Item Functioning of the Satisfaction with Appearance Scale in Systemic Sclerosis: A Comparison Across Sex, Race/Ethnicity and Disease Subtype
Lisa Jewett¹, Linda Kwakkenbos², Vanessa L. Malcarne³, Marie-Eve Carrier² and Brett D. Thombs⁴, ¹Department of Psychiatry, McGill University, Montreal, QC, Canada, ²McGill University, Montreal, QC, Canada, ³SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA, ⁴Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada
Background/Purpose: The Satisfaction with Appearance Scale (SWAP) has been used to assess dissatisfaction with appearance and social discomfort relative to disfigurement in systemic sclerosis (scleroderma,…
Abstract Number: 1880 • 2016 ACR/ARHP Annual Meeting
A Large Proportion of Patients in an Early Systemic Sclerosis-Associated Interstitial Lung Disease Cohort Have Coexisting Pulmonary Hypertension
Amber Young¹, Caitlyn Fisher¹, Rajaie Namas², Holly Wilhalme³ and Dinesh Khanna⁴, ¹Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Department of Medicine [Division of Rheumatology], University of Michigan, Ann Arbor, MI, ³University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴University of Michigan, Ann Arbor, MI
Background/Purpose: Systemic Sclerosis (SSc) is a multi-organ system disease manifested by fibrosis, vascular damage and dysregulation of the immune system. The leading causes of death…
Abstract Number: 2019 • 2016 ACR/ARHP Annual Meeting
Faces in Motion: Clinical Subtyping in Scleroderma Using Changes in Forced Vital Capacity
Colin Ligon¹, Peter Schulam², Suchi Saria³, Fredrick M. Wigley⁴, Robert Wise⁵ and Laura K. Hummers⁶, ¹Rheumatology, University of Pennsylvania School of Medicine, Philadelphia, PA, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ⁴Rheum Div/Mason F Lord, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Department of Pulmonology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Prognostication in scleroderma has historically depended on using static measures such as antibody status and extent of skin involvement to stratify risk of mortality…
Abstract Number: 2895 • 2016 ACR/ARHP Annual Meeting
Adaptation of UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract 2.0 Questionnaire into Turkish
Murat Yasar Tas¹, Gozde Dervis Hakim², Pembe Keskinoglu³, Gokce Kenar⁴, Handan Yarkan⁵, Berrin Zengin⁴, Gerçek Can⁵, Fatos Onen⁴, Nurullah Akkoc⁴, Mesut Akarsu⁶ and Merih Birlik⁴, ¹Internal Medicine, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey, ²Gastroenterology, Ataturk State Hospital, Sinop, Turkey, ³Department of Biostatistics and Medical Informatics, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey, ⁴Rheumatology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey, ⁵Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey, ⁶Gastroenterology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey
Background/Purpose: Nearly 90% of patients with scleroderma (SSc) have gastrointestinal tract(GIT) involvement in variable severities and is a challenging process for clinicians.The University of California…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].